Antibody to hepatitis B core antigen (anti-HBc) is considered
In this study, we utilized two methods to measure seromarkers of HBV infection in serum samples from 133 persons a sensitive and specific serum marker of hepatitis B virus (HBV) infection [1] . Anti-HBc can be found in serum samples who had anti-HBc as the sole marker of HBV infection. We also used PCR analysis to determine if HBV DNA was present. from persons who have been exposed to HBV. Most persons who have been infected with HBV and have recovered have
We correlated our findings with responses to hepatitis B vaccine that we have previously reported [2] . antibody to hepatitis B surface antigen (anti-HBs), and those who are actively infected also have hepatitis B surface antigen (HBsAg).
Patients and Methods The significance of finding anti-HBc as the sole marker of All 133 subjects had participated in a study examining the HBV infection remains uncertain. This finding could be due response to hepatitis B vaccine in persons with only anti-HBc to false-positive results of reactivity tests, particularly when [2] . Participants were persons who were positive for anti-HBc testing is performed by EIA (the method most used by commerbut negative for HBsAg and anti-HBs when tested by EIA cial laboratories and blood banks [2, 3] ); the loss of anti-HBs (Auszyme, Auszab, and Corzyme, Abbott Laboratories, North with time or failure of persons to develop anti-HBs after HBV Chicago, IL) before vaccination. Prevaccination serum samples infection; and the ''window'' phase of acute HBV infection, were also tested for HBsAg, anti-HBs, and anti-HBc by RIA which occurs after the loss of HBsAg and before anti-HBs (AUSRIA II, Ausab, and Corab, Abbott Laboratories). Subjects appears. In these cases anti-HBc IgM is almost always present, were divided into four groups according to their anti-HBc and an HBV carrier state where there is undetectable HBsAg and anti-HBs status (table 1) . Anti-HBs levels in participants were low levels of HBV replication [4] .
again measured by RIA 1 month after the first and third doses of plasma-derived hepatitis B vaccine (20 mg per dose; Heptavax, Merck Pharmaceuticals, West Point, PA). A booster response was defined as development of §50 sample ratio units (SRU) 133 samples revealed that all 128 samples that were initially methods that most serum samples positive for anti-HBc by EIA, but negative by RIA, have low levels of anti-HBc [3] . In negative were again negative and that four of the five positive samples remained positive. Additional samples from each of contrast, serum samples positive only for anti-HBc by both methods have high levels of anti-HBc when quantitated by these positive patients (two to five per patient), which were obtained at different dates (range, 1 -5 years apart), were tested RIA. Thus, raising the positive cutoff level for EIA or employing RIA for determination of anti-HBc would eliminate for HBV DNA by PCR analysis. None of these samples were positive.
some of the false-positive results.
In four other studies investigating serum samples positive Most persons in each group had a primary response to three doses of hepatitis B vaccine, and only a few had a booster only for anti-HBc by either RIA or EIA, PCR analysis revealed HBV DNA in õ10% of samples in three studies [7, 9 , 10] and response to one dose (table 1) . Of those persons who were positive for HBV DNA by PCR analysis, three had a booster in 35% of samples in one study from China [8] . It is likely that the proportion of persons with sera positive only for antiresponse to one dose of hepatitis B vaccine, and two did not. One of the two persons who did not have a booster response HBc who are positive for HBV DNA will be higher among populations with a high prevalence of HBV infection. received three doses of vaccine and had a primary response.
Although a few reports have implicated persons with only anti-HBc as the source of posttransfusion hepatitis B, it would Discussion be both expensive and time-consuming for blood banks to screen samples that are HBsAg-negative but anti-HBc-positive The prevalence of isolated anti-HBc in various populations for HBV DNA by PCR analysis. It would be more practical has ranged from 0.1% to 20% [2] . Among Alaskan natives, for blood banks to continue to exclude those samples that are the prevalence of isolated anti-HBc is 3%. The results of our anti-HBc-positive. study, which was conducted in an area where the prevalence
In conclusion, in this study, HBV DNA was not found in of HBV infection is moderate, imply that the finding of isolated 96% of serum samples from individuals with only anti-HBc anti-HBc in most persons by EIA is a false-positive result.
when tested by EIA. Since most of these persons had a primary Over 80% of persons with isolated anti-HBc in our study had response to hepatitis B vaccine, the finding of isolated antia primary response to hepatitis B vaccine, and HBV DNA was HBc is most likely to be a false-positive result. When a person present in serum samples from õ4% of these persons.
who is screened for hepatitis B vaccination by EIA is found Most clinical laboratories and blood banks use EIA to test to have isolated anti-HBc in their serum, the most practical for seromarkers of HBV infection. RIA appears to be more approach would be to offer the person the hepatitis B vaccine specific for anti-HBc than EIA. In this study, 26% of persons and evaluate their response to vaccination. who were positive for anti-HBc by EIA were negative by RIA; only three (9%) of 35 persons had a booster response to one dose of hepatitis B vaccine, while 24 (92%) of 26 of those In addition, we have previously shown by comparing these two / 9c4a$$ap04 03-07-98 01:12:28 cidas UC: CID
